Mechanism Of Action

PROVENGE® (sipuleucel-T) immunotherapy is designed to target and attack prostate cancer cells

PROVENGE is the first and only FDA-approved immunotherapy for asymptomatic or minimally symptomatic mCRPC

Targeted Mechanism of Action1
6:46
6:46
<div class=">
<div class=">
Wistia video thumbnail - DENPRO-MOA-FINAL-v009
message

The recombinant antigen used to make PROVENGE is PAP-GM-CSF. It consists of prostatic acid phosphatase (PAP), an antigen expressed in more than 95% of prostate cancers, and granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-cell activator.1

Dendreon uses cookies to analyze traffic, enhance your experience, and provide you with tailored content. By continuing to use this site, you agree with our use of cookies and our Privacy Policy. For more information or to opt-out of sale, visit our Privacy Policy.